NASDAQ: NUWENuwellis Inc Stock
$0.28-0.06 (-17.65%)
Updated Apr 17, 2024
NUWE Price
$0.28
Fair Value Price
N/A
Market Cap
$1.89M
52 Week Low
$0.27
52 Week High
$5.73
P/E
-0.02x
P/B
0.63x
P/S
0.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.86M
Earnings
-$20.21M
Gross Margin
56.2%
Operating Margin
-188.61%
Profit Margin
-255.3%
Debt to Equity
2.19
Operating Cash Flow
-$18M
Beta
0.43
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NUWE Overview
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NUWE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUWE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NUWE is good value based on its book value relative to its share price (0.63x), compared to the US Medical Devices industry average (3.66x)
P/B vs Industry Valuation
NUWE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NUWE due diligence checks available for Premium users.
Be the first to know about important NUWE news, forecast changes, insider trades & much more!
NUWE News
Valuation
NUWE fair value
Fair Value of NUWE stock based on Discounted Cash Flow (DCF)
Price
$0.28
Fair Value
$10.77
Undervalued by
97.40%
NUWE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NUWE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
28.84x
Market
41.64x
NUWE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
3.66x
NUWE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NUWE's financial health
Profit margin
Revenue
$2.6M
Net Income
-$5.5M
Profit Margin
-310.7%
NUWE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NUWE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.8M
Liabilities
$6.6M
Debt to equity
2.19
NUWE's short-term assets ($8.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUWE's short-term assets ($8.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUWE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NUWE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$36.0k
Financing
$1.6M
NUWE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NUWE vs Medical Device Stocks
Nuwellis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.